DL
Daniel S. Lorrain
Chief Scientific Officer

Daniel S. Lorrain insider trades: Contineum Therapeutics (CTNM) stock sales

Chief Scientific Officer, Contineum Therapeutics Last trade Jul 9, 2026 13 Form 4 filings
$967K
Sold, last 12 months
8 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2024
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Daniel reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 9, 2026CTNM↓ Sell$17K
Jul 1, 2026CTNM↓ Sell$595K
Apr 6, 2026CTNM↓ Sell$56K
Mar 2, 2026CTNM↓ Sell$63K
Feb 25, 2026CTNM↓ Sell$130K
Feb 19, 2026CTNM↓ Sell$2K
Feb 3, 2026CTNM↓ Sell$62K
Jan 5, 2026CTNM↓ Sell$44K
Nov 25, 2024CTNM↓ Sell$16K
Nov 18, 2024CTNM↓ Sell$101K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other CTNM insiders

Open-market trades in the last 12 months

About Daniel S. Lorrain's insider trades

Daniel S. Lorrain is Chief Scientific Officer at Contineum Therapeutics (CTNM). Since Nov 18, 2024, Daniel has reported no open-market purchases and 10 sales worth $1.1M on SEC Form 4. In the last 12 months: 8 sales ($967K).

Their filings also include option exercises (4 filings), grants and awards (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CTNM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.